Investment Centers of America Inc. cut its holdings in Celgene Corporation (NASDAQ:CELG) by 20.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,369 shares of the biopharmaceutical company’s stock after selling 2,127 shares during the period. Investment Centers of America Inc.’s holdings in Celgene Corporation were worth $1,086,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Neuberger Berman Group LLC lifted its position in Celgene Corporation by 4.0% in the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after purchasing an additional 71,729 shares during the last quarter. Grisanti Capital Management LLC bought a new stake in Celgene Corporation in the 2nd quarter valued at about $3,616,000. Lincoln Capital Corp lifted its position in Celgene Corporation by 0.6% in the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 185 shares during the last quarter. RiverPoint Capital Management LLC lifted its position in Celgene Corporation by 3.1% in the 2nd quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after purchasing an additional 3,680 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Celgene Corporation by 9.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after purchasing an additional 54,210 shares during the last quarter. 79.48% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/11/21/investment-centers-of-america-inc-decreases-stake-in-celgene-corporation-celg.html.

Several analysts recently weighed in on the stock. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 price objective (up from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. William Blair reiterated an “outperform” rating on shares of Celgene Corporation in a research report on Friday, October 20th. BMO Capital Markets reiterated an “outperform” rating and issued a $160.00 price objective (up from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Finally, Leerink Swann restated a “buy” rating and set a $156.00 price target on shares of Celgene Corporation in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $139.87.

Shares of Celgene Corporation (NASDAQ:CELG) opened at $103.15 on Tuesday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a one year low of $94.55 and a one year high of $147.17. The firm has a market cap of $81,210.00, a price-to-earnings ratio of 16.27, a PEG ratio of 0.80 and a beta of 1.79.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.58 EPS. research analysts anticipate that Celgene Corporation will post 6.67 EPS for the current fiscal year.

In related news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the transaction, the director now owns 9,250 shares of the company’s stock, valued at $1,286,027.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,227 shares of company stock valued at $2,843,956. Corporate insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.